Medullary thyroid carcinoma (MTC) is a rare endocrine malignancy, which accounts for ∼5% of all thyroid carcinomas. It derives itself from the calcitonin-secreting, parafollicular C cells of the thyroid gland ([@bib3]). Unlike other thyroid malignancies, MTC shows a strong hereditary predisposition. Approximately 25% of all cases are associated with an activating germline mutation of the REarranged during Transfection (RET) proto-oncogene ([@bib11]; [@bib50]). RET encodes for a receptor tyrosine kinase that influences cell death and differentiation as well as migration and cell cycle progression. Interestingly, RET gain-of-function mutations are also present in the majority of sporadic MTCs ([@bib17]).

Hereditary MTCs are associated with multiple endocrine neoplasia syndromes type 2A and B (MEN2A/B). While both syndromes harbour different extrathyroidal endocrine manifestations such as pheochromocytoma or primary hyperparathyroidism, MTC is the dominant clinical sign, present in almost all the patients ([@bib13]; [@bib24]; [@bib57]).

To date, depending on the preoperative staging and the serum level of calcitonin radical thyroidectomy with or without lymphadenectomy remains the only curative treatment option for MTC patients ([@bib1]; [@bib12]). However, the majority of patients harbour regional or distant metastases at the time of diagnosis, rendering surgery alone insufficient. Hence, the development of new systemic therapeutic regimes based on the ever-improving understanding of MTC oncogenesis has been in the focus of clinical researchers worldwide ([@bib54]). The common alteration of the RET proto-oncogene in sporadic as well as in hereditary MTC has placed the emphasis on tyrosine kinase inhibitors (TKI). This led to the inclusion of TKI as standard of care for patients with advanced MTC. However, the small molecule TKI could thus far not live up to their expectations ([@bib16]; [@bib46]). Once the tumour has spread the 10-year survival rate remains poor with only 21% ([@bib1]).

Metastatic spread is the most relevant prognostic determinant in MTC. Although different pathways like the activation of the RET proto-oncogene and the overexpression of epidermal as well as vascular endothelial growth factor receptor have been implicated with metastatic MTC ([@bib28]), the specific cellular factors determining tumour cell invasion and subsequent metastasis are thus far uncertain. However, to develop new treatment strategies for this subset of patients a better understanding of the molecular pathways involved appears mandatory. The forming of metastases is a closely coordinated and organ-specific procedure, which offers many similarities to that of leukocyte trafficking, a procedure closely monitored by chemokines and their respective receptors ([@bib34]; [@bib33]). In this regard, C-X-C chemokine receptors type 4 and 7 (CXCR4, CXCR7) as well as its ligand stromal cell-derived factor 1 alpha (SDF1*α*), also known as CXCL12, have been implicated in various types of carcinomas ([@bib47]). The G protein-coupled chemokine receptor CXCR4 is expressed in a wide range of tissues during embryogenesis, including the immune and central nervous systems. It plays an important role during angiogenesis and is mandatory for haematopoietic progenitors ([@bib41]). The outstanding role of CXCR4 and its ligand is further underlined by the fact that its loss of function causes embryologic death. This circumstance is rarely observed for other chemokine or G protein-coupled receptors in general ([@bib49]; [@bib40]). Differential expression of CXCR4 is further involved in regulating stem cell trafficking, cerebellar development and immune response. While mostly absent under physiological conditions in many adult tissues, CXCR4 is overexpressed in a variety of human carcinomas ([@bib2]; [@bib36]). In this regard, regional hypoxia in the tumour mass causes the release of Hypoxia-inducible factor 1 (HIF-1) into the tumour microenvironment, which in turn facilitates the upregulation of CXCR4, prompting tumour cell survival through metastatic spread ([@bib41]).

SDF1*α* is a broadly expressed chemokine, which functions as a potent chemoattractant for CXCR4-expressing cells. It is highly expressed in the most common metastatic organs like lymph nodes, liver, lung and bone ([@bib43]; [@bib39]; [@bib61]). Different studies have shown that CXCR4-positive cells follow a chemokine gradient to SDF1*α*-expressing tissues to form distant metastases. Besides chemotaxis, binding of SDF1*α* to CXCR4 causes the activation of intracellular pathways, which are associated with epithelial--mesenchymal transition (EMT), proliferation and survival ([@bib47]).

In addition to CXCR4, SDF1*α* also binds to CXCR7, a chemokine receptor found to be significantly upregulated in different types of epithelial tumours ([@bib15]; [@bib42]; [@bib9]). It has been demonstrated that CXCR7 promotes tumour cell survival by inhibiting apoptosis and facilitates colony formation through increased focal adhesion properties ([@bib8]). Other studies suggested that CXCR7 functions as a co-receptor to CXCR4, thus enhancing SDF1*α*-mediated G protein signalling ([@bib25]; [@bib47]).

The aim of our study was to investigate the stage-dependent expression of CXCR4 and CXCR7 in MTC and to elucidate the functional implications of the CXCR4/CXCR7/CXCL12 axis in MTC.

Materials and methods
=====================

Patient selection and clinicopathological data
----------------------------------------------

All patients who underwent all types of thyroidectomy for histologically confirmed MTC, irrespective of tumour stage and microscopic resection margin, at the Department of Surgery (A), University Hospital Duesseldorf between 1986 and 2003 were retrospectively reviewed and included in this study. Our exclusion criteria comprised incomplete pathological report, missing clinical data, incomplete resection or insufficient tissue material for subsequent analysis. Follow-up data were obtained from our prospectively maintained clinical database. Overall survival was defined as the time in months from the date of surgery until death of any cause or until the last follow-up at which survivors were censored. Patients who died within the first 30 days upon surgery were not included in the survival analysis. Clinical data including sex, age at first diagnosis, serum calcitonin levels prior to surgery, genetic profiles regarding sporadic and inherited MTC as well as the initial tumour stage were retrospectively reviewed. During the time of the study different calcitonin assays had been used. Here we focussed on the numeric calcitonin basal blood levels prior to surgery irrespective of the assay method employed. Medullary thyroid carcinomas were staged according to the 8th edition of the UICC classification ([@bib5]).

The study was carried out in accordance to Good Clinical Practice, the Declaration of Helsinki and local rules as well as regulations of the country. Strict anonymity of all patients' data were established and maintained throughout the study. An approval from the institutional ethics committee of the Medical Faculty, Heinrich Heine University Duesseldorf was obtained (reference number: 3821).

Tissue microarray and immunohistochemistry
------------------------------------------

All formalin-fixed paraffin-embedded tissue samples were provided from the Institute of Pathology, University Hospital Duesseldorf. The construction of the tissue microarrays, immunohistochemistry and analysis of protein expression using the immunoreactivity score (IRS) reported by Remmele ([@bib37]) were performed as described previously ([@bib59]). The staining intensity of the different samples was reviewed by two independent investigators (TW and CF) in a blinded manner.

For immunohistochemical staining the following primary antibodies were used: mouse monoclonal anti-CXCR4 (1 : 100 dilution; Abcam, Cambridge, UK), rabbit polyclonal anti-CXCR7 (1 : 200 dilution; GeneTex, Irvine, CA, USA).

Isotype controls were performed using mouse IgG1k (MOPC-21; 1 : 50 dilution; Abcam) or rabbit immunoglobulin fraction (Code X0903; 1 : 1000 dilution; Dako, Glostrup, Denmark). CXCR4-expressing tonsil tissue and CXCR7-expressing pancreatic adenocarcinoma served as positive controls. The prognostic power of CXCR4 and CXCR7 was assessed according to the REporting recommendations for tumour MARKer prognostic studies (REMARK) ([@bib31]).

Cell culture and reagents
-------------------------

The human MTC cell line TT was purchased from the American Type Culture Collection (ATCC, Middlesex, UK; CRL-1803). The cell line was cultivated in F-12K medium (Gibco Thermo Fisher, Waltham, MA, USA), supplemented with 10% foetal bovine serum. Cell line authenticity was confirmed as described previously ([@bib20]). Recombinant human (rh) SDF1*α* was purchased from PeproTech (Rocky Hill, NJ, USA). Specific CXCR4 antagonist plerixafor (AMD3100) and WZ811 were obtained from Selleck Chemicals (Houston, TX, USA).

Invasion assay
--------------

TT cells were treated with different concentrations of rh-SDF1*α*, AMD3100, WZ811 or vehicle control at equimolar concentrations for 24 h in serum-starved culture medium. Afterwards, cells were harvested and seeded on BD Matrigel invasion chambers (BD Biosciences, Heidelberg, Germany) at a density of 5 × 10^4^ cells ml^−1^ in F-12K medium supplemented with 0.25% bovine serum albumin. Conditioned Dulbecco's Modified Eagle Medium from CXCL12-expressing NIH 3T3 fibroblasts ([@bib6]; [@bib22]) was used as chemoattractant and added to the lower chamber. After 24 h of incubation, cells were fixed with methanol and stained with 4′,6-diamidin-2-phenylindol (DAPI; 200 ng ml^−1^). 4′,6-diamidin-2-phenylindol-positive cells were counted in five visual fields of three separate membranes under a fluorescence microscope at × 200 magnification (Zeiss Axioplan 2, Carl Zeiss, Göttingen, Germany).

FACS cell cycle analysis
------------------------

TT cells were treated with different concentrations of rh-SDF1*α*, AMD3100, WZ811 or vehicle control at equimolar concentrations for 48 h. For subsequent cell cycle analysis, TT cells were harvested and washed in cold PBS and resuspended in 80% ethanol. After incubation for 2 h, cells were washed in PBS and incubated with RNAse A (100 *μ*g ml^−1^) and propidium iodide (PI; 50 *μ*g ml^−1^) for 30 min at 37 °C. Finally, cells were analysed by fluorescence-activated cell sorting (FACS) using a BD FACSCanto II (BD Biosciences, San Jose, CA, USA).

BrdU proliferation assay
------------------------

Cell proliferation was assessed in 96-well culture plates with cells plated at a concentration of 4 × 10^3^ per well under serum-starved culture conditions. After 24 h cells were incubated for 48 h with rh-SDF1*α*, AMD3100, WZ811 or vehicle control at equimolar concentrations. To assess cell proliferation the Cell Proliferation ELISA, BrdU assay (Roche Applied Science, Mannheim, Germany) was performed at an absorbance at 370 nm according to the manufacturer's protocol. All assays were analysed using an Infinite 200 microplate reader (Tecan Group Ltd., Crailsheim, Germany).

Western blot analysis
---------------------

For protein isolation, cells were lysed in ice-cold RIPA buffer. Total protein concentrations were measured using a BioPhotometer (Eppendorf, Hamburg, Germany). Proteins were separated using SDS--polyacrylamid gel electrophoresis and transferred onto a nitrocellulose membrane for antibody-detection. Membranes were incubated overnight using the following primary antibodies: mouse monoclonal anti-CXCR4 (1 : 100 dilution; Abcam), rabbit polyclonal anti-CXCR7 (1 : 200 dilution; GeneTex).

Immunocytochemistry
-------------------

Cells were fixed with ice-cold methanol and incubated with 0.5% Triton. Unspecific epitops were blocked using 20% AB serum. Next, cells were incubated with their respective primary antibody or isotype control (mouse monoclonal anti-CXCR4, 1 : 250 dilution; Abcam; rabbit polyclonal anti-CXCR7, 1 : 500 dilution; GeneTex; mouse IgG1k (MOPC-21); 2 *μ*g ml^−1^; Abcam; rabbit immunoglobulin fraction (Code X0903) 2 *μ*g ml^−1^; Dako). After 45 min of incubation, cells were washed and treated with either anti-mouse- or anti-rabbit-Alexa Fluor 488 (10 *μ*g ml^−1^; Thermo Fisher). Nuclear staining was achieved using DAPI (200 ng ml^−1^). After fixation with 1% PFA, the cells were visualised using a fluorescence microscope at × 400 magnification (Zeiss Axioplan 2, Carl Zeiss).

RT--PCR
-------

Total RNA was extracted from cells using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was synthesised from 2 *μ*g of total RNA using the qScript cDNA Synthesis Kit (QuantaBio, Beverly, MA, USA) following the manufacturer's instructions. The cDNA was then adjusted to a final concentration of 1 ng *μ*l^−1^. For the subsequent quantitative real-time-PCR (qRT--PCR), 2 *μ*l of cDNA template were mixed with 10 *μ*l PerfeCTa Fast Mix II (QuantaBio), 0.2 *μ*l probe (100 n[M]{.smallcaps}; Roche) and 0.2 *μ*l of forward and reverse primer (200 n[M]{.smallcaps} each). All templates were run as triplicates. Glyceraldehyde-3-phosphate dehydrogenase served as internal reference gene. The primers used are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. All experiments were performed on the DyadDisciple Chromo 4 (Bio-Rad) using the following set-up: 95 °C for 2 min, followed by 40 cycles of denaturation at 95 °C for 10 s and annealing and extension at 60 °C for 30 s. Gene expression was quantified according to the 2^−▵▵CT^ method ([@bib29]).

Statistical analysis
--------------------

Correlations between the IRS of CXCR4 or CXCR7 and the respective clinicopathological parameters were evaluated by logistic regression analyses and the non-parametric Spearman correlation. Changes in chemokine receptor expression between groups were assessed using the non-parametric Mann--Whitney *U* test or the Wilcoxon matched-pairs signed rank test as indicated. In addition, the data were categorised according to the respective mean IRS and analysed by the Fisher's exact test. Univariate survival analyses were performed by the log-rank (Mantel--Cox) test. Cox regression analyses were used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for multivariate analyses including all variables. Moreover, a search for the best model was conducted using a stepwise variable selection procedure based on the Akaike Information Criterion (AIC). Cell culture experiments were repeated at least three times and evaluated for statistical significance using the non-parametric Mann--Whitney *U* test.

Statistical analyses were computed using GraphPad Prism (Version 6, GraphPad Software, San Diego, CA, USA) and the Statistical Software R version 3.1.0. A *P*-value \<0.05 was considered statistical significant.

Results
=======

Patients and outcome
--------------------

Overall 86 patients were included in our study. The patients' characteristics are illustrated in [Table 1](#tbl1){ref-type="table"}. The median overall survival in our cohort of patients was 170 months (range 5--287) with a median follow-up of 191 months (range 5--287) based on the reverse Kaplan--Meier procedure. The last follow-up was performed in January 2013. During this period of time 19 patients died. Owing to loss of follow-up, 11 patients were unavailable for subsequent survival analysis. The calcitonin basal blood levels prior to surgery were available for 67 patients, with a median of 304 pg ml^−1^. The genesis of the malignancy, whether sporadic or inherited, was known for the majority of patients. Only for eight patients the genetic profile was unavailable. While there were differences in surgical treatment between the patients, owed to the given recommendations at the respective time, the great majority of patients underwent radical, total thyroidectomy.

Expression of CXCR4 correlates with advanced tumour stage and metastatic phenotype
----------------------------------------------------------------------------------

First, we compared the IRS of the two chemokine receptors in MTC samples and corresponding non-neoplastic thyroid tissues, lymph node as well as distant metastases. Whereas primary tumour samples and corresponding metastases stained strongly positive for CXCR4, normal thyroid tissue samples exhibited predominantly no expression of CXCR4 (*P*\<0.001; [Figure 1A and B](#fig1){ref-type="fig"}). In contrast, almost all tissue specimens stained negatively for CXCR7 in both tumour and corresponding unaffected tissue cores. Only one primary tumour exhibited a strong expression for CXCR7, whereas three lymph node metastases demonstrated a weak expression for CXCR7 (data not shown).

To further investigate a possible association between different clinicopathological parameters and CXCR4 expression, the IRS for CXCR4 was compared across groups of different clinicopathological variables. Interestingly, we found a strong association between high CXCR4 expression and large tumour size (T1/2 *vs* T3/4: *P*\<0.01; [Figure 2A](#fig2){ref-type="fig"}) as well as advanced tumour stages (UICC I/II *vs* UICC III/IV: *P*\<0.001; [Figure 2B](#fig2){ref-type="fig"}). In addition, patients with lymph node or distant metastases exhibited a significantly higher expression of CXCR4 in their primary tumour cores when compared to patients' samples without metastases (N neg. *vs* N pos.: *P*\<0.001; M0 *vs* M1: *P*\<0.01; [Figure 2C and D](#fig2){ref-type="fig"}). Of note, CXCR4 was also significantly higher expressed in the lymph node metastases than in the corresponding primary tumour (*P*\<0.001; [Figure 1B](#fig1){ref-type="fig"}). Moreover, tumours from patients with a sporadic genesis of their disease and advanced age at the time of first diagnosis exhibited markedly higher expression levels of CXCR4 (sporadic *vs* MEN2A: *P*\<0.001; Age\<median *vs* Age⩾median: *P*\<0.05; [Figure 2E and F](#fig2){ref-type="fig"}). Using CXCR4 as a continuous variable, the logistic regression analysis further confirmed the strong correlation between increasing expression levels of CXCR4 and larger tumour diameter, reflected by high T3/4 stage (rs=0.547; 95% CI: 0.373--0.683; *P*\<0.001), and the presence of lymph node (rs=0.563; 95% CI: 0.394--0.696; *P*\<0.001) and distant metastases (rs=0.354; 95% CI: 0.147--0.531; *P*\<0.001; [Figure 2G](#fig2){ref-type="fig"}).

These findings were confirmed by categorising the CXCR4 expression into high (IRS⩾median) and low (IRS\<median) and comparing the expression levels with regard to the different clinicopathological parameters by using the Fisher's exact test ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

CXCR4 expression is a negative prognostic marker in MTC
-------------------------------------------------------

To further explore a prognostic relevance of CXCR4 in MTC univariate survival analyses were performed. Accordingly, a high CXCR4 expression was strongly associated with a poor overall survival in MTC patients (HR=4.474; 95% CI: 1.671--11.98; *P*\<0.001; [Table 2](#tbl2){ref-type="table"}). In addition, other clinicopathological markers such as old age at first diagnosis, sporadic MTC, present lymph node or distant metastases and advanced T3/T4 tumour stages predicted poor prognosis ([Table 2](#tbl2){ref-type="table"}).

In the subsequent multivariate analysis including all variables, no clinicopathological parameter came up as an independent negative prognostic marker ([Table 2](#tbl2){ref-type="table"}). However, the implementation of a variable selection procedure based on the AIC identified the presence of distant metastases at the time of first diagnosis to be an independent prognostic factor ([Table 2](#tbl2){ref-type="table"}). Importantly, the AIC decreased during the stepwise variable selection by 10 units, proving a better goodness of fit of the selection model and indicating its higher relevance in our set of data ([@bib7]).

Rh-SDF1*α* induces CXCR4-dependent tumour cell invasion
-------------------------------------------------------

To date, only one study using a papillary thyroid carcinoma cell line demonstrated a potential role of the SDF1α/CXCR4 axis in initiating tumour cell invasion and migration in thyroid carcinoma ([@bib64]). Since this functional relevance has not yet been reported for MTC, we took advantage of the MTC cell line TT, which expresses both chemokine receptors CXCR4 and CXCR7 as revealed by immunocytochemistry and western blot analyses ([Figure 3A and B](#fig3){ref-type="fig"}). To investigate the impact of SDF1-driven invasiveness, we treated TT cells with increasing concentrations of rh-SDF1*α* and measured the changes in invasive growth. Rh-SDF1*α* induced a significant increase in the number of invading cells by a fold change of 1.5 as compared to cells treated with vehicle control (*P*\<0.01; [Figure 4A and B](#fig4){ref-type="fig"}).

Next, we treated the cells with the well-described CXCR4 antagonists AMD3100 and WZ811. The incubation with the respective compounds markedly reduced the invasive capacity of the MTC cells. For both compounds the effect was more profound at higher concentrations suggesting a dose-dependent mechanism. The incubation with WZ811 at 100 n[M]{.smallcaps} reduced the amount of invasive cells to 0.59 fold of the amount of control-treated cells (*P*\<0.05) while the incubation with 1 *μ*[M]{.smallcaps} caused a decrease in invasive cells by a fold change of 0.45 (*P*\<0.01; [Figure 4A and B](#fig4){ref-type="fig"}). Similarly, the effect of AMD3100 became more obvious at 1 *μ*[M]{.smallcaps} than at 100 n[M]{.smallcaps} inducing a fold change of 0.53 of invading cells as opposed to 0.68 when compared to vehicle control-treated cells (*P*\<0.01; [Figure 4A and B](#fig4){ref-type="fig"}). Interestingly, the inhibitory effect of the respective chemokine receptor antagonists persisted when the cells were co-incubated with rh-SDF1*α* (data not shown).

Rh-SDF1*α* induces invasiveness through cell cycle activation and EMT
---------------------------------------------------------------------

To further elucidate the possible mechanisms behind the increase in invasiveness after incubation with rh-SDF1*α* we performed cell cycle analyses using FACS technology. The treatment with rh-SDF1*α* resulted in a significant decrease of cells remaining in the G1 phase, while significantly more cells entered the G2/M phase ([Figure 4C](#fig4){ref-type="fig"}). Interestingly, these changes in cell cycle activation did not translate into an increase in cell proliferation (data not shown). Moreover, incubation of MTC cells with CXCR4 antagonists AMD3100 and WZ811 initiated no changes in cell cycle profiles or proliferation (data not shown).

Next, we investigated possible changes in mRNA expression levels of genes associated with EMT and tumour cell invasion. Whereas rh-SDF1*α* induced no changes in the expression of SNAI1, the expression levels of BST2, FGF9 and Vimentin were significantly upregulated after rh-SDF1*α* treatment (*P*\<0.01; [Figure 4D](#fig4){ref-type="fig"}, [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). On the other hand, expression levels of E-cadherin were markedly reduced after incubation with rh-SDF1*α* (*P*\<0.05; [Figure 4D](#fig4){ref-type="fig"}, [Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Carcinomas of the thyroid gland are the most common endocrine malignancies in the world. They are responsible for more patients' deaths than all other endocrine-associated malignancies combined ([@bib14]). Although surgery may be curative in the early stages of the disease, the majority of patients harbour distant metastases at the time of diagnosis ([@bib17]). Locoregional and distant spread that occur during the early stages of the disease is not rarely the first clinical sign. Once the disease has spread the treatment options with curative intent are limited. In this regard, the discovery and new appreciation of the activating mutation of the RET proto-oncogene in hereditary and sporadic MTC patients has caused paramount changes in adjuvant therapeutic protocols. It has led to the replacement of mainly dacarbazin- and doxorubicin-based chemotherapeutic regimes by small molecule TKI ([@bib23]). However, after the initial euphoria had faded and the limited effects on progression-free survival became apparent, a new appraisal of the commonly altered signalling pathways in carcinogenesis has started to evolve ([@bib27]; [@bib16]; [@bib17]).

CXCR4 has been linked to different tumour entities as a negative prognostic marker and important factor in carcinoma cell homing and subsequent metastasis ([@bib9]; [@bib21]; [@bib32]). Thus far, little is known about the CXCR4/CXCR7/CXCL12 axis in MTC. To our knowledge, only one study has investigated the expression of CXCR4 and CXCR7 in MTC. In a study performed by Zhu *et al* only 10 MTC tissue specimens were immunohistochemically stained for CXCR4 and CXCR7 but no subsequent correlation with clinicopathological variables or functional analyses were performed ([@bib64]). Therefore, our study is the first that investigated the stage-dependent expression of CXCR4 and CXCR7 in MTC patients and further stratified their functional implications *in vitro*.

In our set of patients, CXCR4 was significantly higher expressed in MTC than in non-neoplastic thyroid tissue specimens. In addition, a high CXCR4 expression in the primary tumour was associated with a high probability of an advanced tumour stage, high UICC stage and metastatic phenotype. In the univariate analysis, elevated CXCR4 expression levels were also associated with a significantly worse prognosis. In the multivariate analysis however, only the presence of distant metastases proved to be an independent negative prognostic parameter. Taken together, these findings underscore the paramount importance of metastatic spread for the patients\' outcome on the one hand and on the other draft a concept by which CXCR4 influences this powerful prognostic marker. So while metastatic disease determines the outcome, CXCR4 facilitates its formation.

CXCR7 on the other hand was almost not expressed in our MTC tissue probes, which is in line with the study by Zhu *et al.* There, only endothelial cells of adjacent blood vessels stained partially positive for CXCR7 ([@bib64]).

Considering the pivotal role of CXCR4 for tumour cell dissemination, the significantly higher expression of the chemokine receptor in lymph node metastases compared to the expression in the corresponding primary MTC specimens fits perfectly into our expanding knowledge of the CXCR4/CXCL12 axis in carcinoma. Mechanistically, the homeostatic microenvironment chemokine CXCL12 functions as a chemoattractant for CXCR4-expressing cells and modulates intracellular calcium flux, cell cycle activation and chemotaxis ([@bib32]). This in turn leads to the initiation of different cell signalling pathways, which promote EMT, the forming of an invasive phenotype and tumour cell progression ([@bib45]; [@bib53]; [@bib63]).

Our functional *in vitro* experiments demonstrated for both CXCR4 antagonising compounds AMD3100 and WZ811 a significant reduction in the number of invading cells. These observations are in line with the current literature where multiple studies have shown an anti-metastatic effect for both compounds. WZ811 exhibits a profound anti-tumourigenic potential in chronic lymphocytic leukaemia and negatively influences CD3-positive T-cell migration both *in vitro* and *in vivo* ([@bib18]; [@bib26]). AMD3100 on the other hand is known to reduce the metastatic potential in small cell lung carcinoma ([@bib51]), breast cell carcinoma ([@bib58]) and oral squamous cell carcinoma ([@bib55]). Its predominant clinical application, however, is its capacity to mobilise haematopoietic stem cells from the bone marrow after transplantation for haematopoietic malignancies. Since cell migration in and out of the bone marrow follows opposite chemokine gradients, AMD3100 has proven itself a useful asset, especially in patients predicted to be poor stem cell mobilisers ([@bib4]; [@bib10]).

The fact that a co-incubation with rh-SDF1*α* could not overcome the inhibitory effect of the two CXCR4-specific antagonists in a cell model where both CXCR4 and CXCR7 were equally expressed, suggests that a functioning CXCR4 is mandatory for the CXCR4/CXCR7/CXCL12 axis to fully evolve in MTC and cannot be entirely compensated by CXCR7 alone. Notably, one study by Kalatskaya *et al* even suggests AMD3100 as a ligand to CXCR7 with allosteric agonist properties, questioning not only its CXCR4-specificity but also its functionality ([@bib19]). These observations support the hypothesis that CXCR7 functions as regulator to CXCR4 G protein signalling ([@bib44]; [@bib48]). However, further functional experiments are warranted to fully elucidate the complex interaction between CXCR4, CXCR7 and their mutual ligand CXCL12.

The incubation of MTC cell line TT with rh-SDF1*α* resulted in an activation of cell cycle and subsequent increase in the number of invading cells. Of note however, the increase in cell count in the G2/M phase did not translate into an increase in cell proliferation as investigated by BrdU colorimetric ELISA assay. The discrepancy may be attributed to the slow doubling time of the cell line and the fact that all *in vitro* studies were conducted in serum-starved culture medium. Owing to these circumstances, the respective lengths of the incubation periods of the MTC cell line were limited as the cultured cells succumbed to serum starvation and did not incorporate BrdU in a sufficient manner to corroborate the results from the FACS analyses.

The CXCR4/CXCR7/CXCL12 axis has been implicated with EMT in different tumour types, which in turn was held responsible for enhanced invasive growth and metastatic spread. As a marker for EMT, we investigated the changes in expression levels for Vimentin and E-cadherin following rh-SDF1*α* treatment. We could demonstrate that the incubation of MTC cell line TT with rh-SDF1*α* resulted in a significant upregulation of Vimentin while the expression of E-cadherin was markedly reduced, suggesting a cellular transition from epithelial to mesenchymal phenotype. Additionally, mRNA levels of EMT-associated transcriptional factors BST2 and FGF9 were markedly upregulated after rh-SDF1*α* treatment.

BST2 is a known activator of NF-*κ*B, whose activation promotes tumour cell invasion and metastasis through EMT ([@bib30]; [@bib62]). In breast carcinoma BST2 has been identified as an independent marker for metastasis, its overexpression causing anchorage independent growth and facilitating invasiveness ([@bib60]). FGF9 on the other hand has been associated with EMT via the upregulation of vascular endothelial growth factor ([@bib52]) and its expression is linked to poor prognosis and a metastatic phenotype in different solid tumours ([@bib56]; [@bib35]; [@bib38]). The increased mRNA expression of these markers may be seen as an indicator of the underlying cellular machinery of the CXCR4/CXCR7/CXCL12-mediated metastatic push, but still requires further investigation to fully appreciate the molecular mechanics.

Since invasive growth and the subsequent formation of distant metastases are the primary deciding factors for fatal outcome, a better understanding of the molecular pathways of tumour cell dissemination and invasion is mandatory in developing new therapeutic strategies. Here, we propose the CXCR4/CXCR7/CXCL12 axis as an important functional determinant in MTC tumour biology. With its distinct expression profile and strong association with disseminated disease, CXCR4 can be considered as a new and viable therapeutic target in advanced MTC. Especially its involvement in the induction of EMT offers new valuable insight into the oncogenesis of MTC and should provide encouragement for further preclinical studies.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![**Expression of CXCR4 in MTC.** (**A**) Representative tissue samples with immunohistochemical staining for CXCR4 and calcitonin in MTC (left), respective lymph node metastasis (middle) and non-neoplastic thyroid gland (right). All shown samples were classified as a strong expression for the given marker in accordance with the IRS. The bar at the top left corner indicates 50 *μ*m. (**B**) Expression levels of CXCR4 in non-neoplastic thyroid tissue specimens and respective corresponding MTC, lymph node and distant metastases. Boxplots display the median IRS with the upper and lower quartile, as well as maximum and minimum for CXCR4. CXCR4 expression in the different tissue samples was compared between groups using the Wilcoxon matched-pairs signed rank test. Bars indicate the respective pairs. CXCR4=C-X-C chemokine receptor type 4; DM=distant metastases; IRS=immunoreactivity score; LN=lymph node metastases; MTC=medullary thyroid carcinoma; NT=non-neoplastic thyroid gland; \*\*\**P*\<0.001.](bjc2017364f1){#fig1}

![**Association between CXCR4 expression and different clinicopathological parameters.** (**A**--**F**) Boxplots display the median IRS with the upper and lower quartile, as well as maximum and minimum for CXCR4 in the primary tumour core grouped according to the given clinicopathological parameter. CXCR4 expression levels were compared using the non-parametric Mann--Whitney *U* test. (**G**) Cox regression analyses demonstrate the correlation between increasing expression levels of CXCR4 and the likelihood of an advanced tumour stage or metastatic phenotype. CXCR4=C-X-C chemokine receptor type 4; IRS=immunoreactivity score; LN=lymph node; \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2017364f2){#fig2}

![**Expression levels of CXCR4 and CXCR7 in MTC cell line TT.** (**A**) Immunocytochemical staining of CXCR4 and CXCR7 in MTC cell line TT using Alexa Fluor 488 as secondary antibody. DAPI was used for visualisation of the nucleus. Overlays demonstrate the composite images for both staining procedures. Antibody specificity was confirmed with isotype controls (control). Images were captured using a fluorescence microscope at × 400 magnification. Bar at the top left corner indicates 50 *μ*m. (**B**) Western blot analysis for both CXCR4 and CXCR7 in MTC cell line TT. GAPDH served as loading control. CXCR4/7=C-X-C chemokine receptor type 4/7.](bjc2017364f3){#fig3}

![**rh-SDF1*α* induces tumour cell invasion, cell cycle activation and EMT.** (**A**) Representative pictures of matrigel invasion membranes stained with DAPI for nuclear visualisation after treatment of human MTC cell line TT with CXCR4 antagonising compounds AMD3100 and WZ811 as well as chemokine receptor agonist rh-SDF1*α*. (**B**) The number of invading cells was estimated by counting cells in five visual fields of at least three separate membranes and illustrated as fold change to control. (**C**) After treatment with rh-SDF1*α*, cell cycle analyses were performed using PI staining and FACS. Cell populations are grouped according to the distinct cell cycle phase. (**D**) Changes in mRNA expression levels of EMT-associated genes were evaluated using qRT--PCR where GAPDH served as housekeeping gene. Fold changes were calculated using the 2^−▵▵CT^ method. All plots display the mean with s.e.m. Numerical data were analysed using the non-parametric Mann--Whitney *U* test. CT values are displayed in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}. Ctrl=vehicle control for the highest concentration; \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2017364f4){#fig4}

###### Patient characteristics (*n*=86)

  **Variables**                                   **No. of patients (%)**
  ---------------------------------------------- -------------------------
  Total                                                     86
  **Age**                                        
  Median (range); years                                 48 (6--83)
  **Gender**                                     
  Male                                                    42 (49)
  Female                                                  44 (51)
  **Genetic**                                    
  Sporadic                                                40 (47)
  MEN2A                                                   38 (44)
  Unknown                                                  8 (9)
  **Basal calcitonin levels prior to surgery**   
  \<12 pg ml^−1^                                          9 (10)
  \>12 pg ml^−1^                                          58 (68)
  Unknown                                                 19 (22)
  **Type of surgery**                            
  *Hemithyroidectomy*                                     11 (13)
  with unilateral ND                                       3 (3)
  *Subtotal thyroidectomy*                                 7 (8)
  with bilateral ND                                        2 (2)
  *Total thyroidectomy*                                   16 (19)
  with unilateral ND                                      16 (19)
  with bilateral ND                                       31 (36)
  **Side affected**                              
  Unilateral                                              70 (81)
  Bilateral                                               16 (19)
  **Tumour stage**                               
  T1/2                                                    67 (78)
  T3/4                                                    19 (22)
  **Lymph node metastasis**                      
  N negative                                              43 (50)
  N positive                                              43 (50)
  **Distant metastasis**                         
  M0                                                      68 (79)
  M1                                                      18 (21)
  **UICC stage**                                 
  UICC I/II                                               41 (48)
  UICC III/IV                                             45 (52)

Abbreviations: MEN2A= multiple endocrine neoplasia type 2A; ND=neck dissection; UICC=Union Internationale Contre le Cancer.

###### Overall survival analysis

  **Variables**                                                           **HR**   **CI (lower**--**upper 95%)**  ***P*****-value**
  ---------------------------------------------------------------------- -------- ------------------------------- -------------------
  **Univariate survival analysis**                                                                                
  Age at first diagnosis                                                  3.740            1.477--9.469           **0.005**
  Sex                                                                     1.893            0.749--4.785           0.178
  T1/2 *vs* T3/4                                                          3.641            1.115--11.89           **0.032**
  N negative *vs* N positive                                              4.773            1.879--12.13           **0.001**
  M0 *vs* M1                                                              21.45            6.304--72.98           **\< 0.001**
  Sporadic *vs* MEN2A                                                     6.289            2.193--18.03           **\< 0.001**
  Calcitonin basal blood level                                            3.688            0.856--15.89           0.080
  CXCR4 expression                                                        4.474            1.671--11.98           **0.003**
  **Multivariate survival analysis**                                                                              
  Age at first diagnosis                                                  3.1662           0.089--1.116           0.074
  Sex                                                                     0.953            0.328--2.766           0.930
  T1/2 *vs* T3/4                                                          1.074            0.360--3.202           0.898
  N negative *vs* N positive                                              2.193            0.401--11.987          0.365
  M0 *vs* M1                                                              2.219            0.558--8.823           0.258
  Sporadic *vs* MEN2A                                                     4.523            0.507--40.300          0.176
  Calcitonin basal blood level                                            0.946            0.313--2.860           0.922
  CXCR4 expression                                                        1.045            0.867--1.261           0.643
  **Multivariate survival analysis after stepwise variable selection**                                            
  M0 *vs* M1                                                              11.47            2.941--44.71           **\<0.001**

Abbreviations: CI=confidence interval; CXCR4=C-X-C chemokine receptor type 4; HR=hazard ratio; MEN2A= multiple endocrine neoplasia type 2A. The bold values are statistically significant.
